Belz 1986.

Methods	4‐week placebo washout; inclusion criteria= DBP 95‐114 mm Hg; 4‐week double‐blind treatment
Participants	Cilazapril 1.25 mg: n=8(4 males,4 females); mean age=47.8(7.1) years; baseline sitting SBP=154.1(10.6) mm Hg, DBP=103.6(6.7) mm Hg; Cilazapril 2.5 mg: n=6(3 males,3 females); mean age=47.2(9.1) years; baseline sitting SBP=149.8(13.2) mm Hg, DBP=100.2(4.4) mm Hg; Cilazapril 5 mg: n=6(2 males,4 females); mean age=51.5(9.1) years; baseline sitting SBP=162.2(24.0) mm Hg, DBP=104.3(5.5) mm Hg; Placebo: n=7(3 males,4 females); mean age=52.7(9.6) years; baseline sitting SBP=148.3(17.3) mm Hg, DBP=98.3(4.9) mm Hg
Interventions	Cilazapril 1.25 mg once daily; Cilazapril 2.5 mg once daily; Cilazapril 5 mg once daily; Placebo; administered in the morning at approximately 7 AM
Outcomes	Peak sitting SBP/DBP
Notes	BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Table 2, p. 526; lying and standing BP data also available; Jadad score=2; funding source= Hoffmann‐La Roche AG
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear